Teva says generic threat to GSK's Advair is limited

11/7/2010 | Reuters

GlaxoSmithKline is not expected to face generic competition soon for its blockbuster inhaled asthma drug Advair, after Teva Pharmaceutical Industries said gaining FDA approval for a copy would be a major challenge. "The world's top generic company has now admitted that there will be no rapid erosion of Advair by generics, which should assuage the fears of even the most skeptical fund manager," an analyst said.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President - Government Products
Health Alliance Plan
Detroit, MI
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Actuary
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
MedCost
Winston-Salem, NC